<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The epidemiology of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> demonstrates a strong gender bias with a sex ratio of 8-9:1 in favor of males </plain></SENT>
<SENT sid="1" pm="."><plain>A potential explanation for this is that <z:chebi fb="0" ids="50114">estrogen</z:chebi> might protect against esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50114">Estrogen</z:chebi> has previously been shown to stimulate <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in esophageal squamous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>However, the effect of <z:chebi fb="0" ids="50114">estrogen</z:chebi> on esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells has not been determined </plain></SENT>
<SENT sid="4" pm="."><plain>We used immunoblotting analysis to determine the expression of <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptors, cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> marker E-cadherin, and proliferation marker Ki-67 in cell lines derived from esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (OE-19, OE-33) and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (QhTRT, ChTRT, GihTRT) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50114">Estrogen</z:chebi> and selective <z:chebi fb="0" ids="50739">estrogen receptor modulator</z:chebi> (SERM)-dependent effects on cell growth were determined by the CellTiter-96 Aqueous Proliferation Assay </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was determined by Annexin V/<z:chebi fb="0" ids="51240">Propidium Iodide</z:chebi> cell labeling and flow cytometry </plain></SENT>
<SENT sid="7" pm="."><plain>We detected that physiological and supra-physiological concentrations of 17Î²-<z:chebi fb="1" ids="23965">estradiol</z:chebi> and SERM decreased cell growth in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> cells (QhTRT, ChTRT), decreased growth was also detected in response to <z:chebi fb="0" ids="50114">estrogen</z:chebi>/SERM </plain></SENT>
<SENT sid="9" pm="."><plain>The level of <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor expression in the cell lines correlated with the level of anti-growth effects induced by the receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Flow cytometry analysis confirmed <z:chebi fb="0" ids="50114">estrogen</z:chebi>/SERM stimulated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="50114">Estrogen</z:chebi>/SERM treatments were associated with a decrease in the expression of Ki-67 and an increase in E-cadherin expression in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells </plain></SENT>
<SENT sid="12" pm="."><plain>This study suggests that esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> cells respond to treatment with selective <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptor ligands, resulting in decreased cell growth and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>Further research to explore potential therapeutic applications is warranted </plain></SENT>
</text></document>